- view as grid
- view as list
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new Kaiser Family Foundation survey. All previous columns by Drew Altman are available online.
In this column for The Wall Street Journal’s Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new survey.
Prescription Drug Costs Remain Atop the Public’s National Health Care Agenda, Well Ahead of Affordable Care Act Revisions and Repeal
28% of Public Report Asking Doctor about a Drug They Saw Advertised, and 12% Say Their Doctor Prescribed It Few Workers Expect Raises if Employers Reduce Health Benefits to Avoid Cadillac Tax as Many Economists Predict With some presidential candidates laying out details of their health care platforms, the cost…
This month’s Kaiser Health Tracking Poll finds that the affordability of prescription drugs continues to be at the top of the public’s priority list for the President and Congress, picked by majorities across political parties. Issues specific to the ACA, such as repealing provisions of the law or repealing the law entirely, fall much lower on the list. The survey also probes the public’s experiences with drug advertisements. A large majority (82%) report they’ve seen or heard such advertising, and 28 percent say they have talked with a doctor about a specific drug they saw advertised. Favorable and unfavorable views of the health care law are tied this month with 42 percent favorable and 42 percent unfavorable. Few uninsured (15 percent) are aware that the third ACA enrollment period begins in November, however many (49 percent) say they expect to get health insurance in the next few months despite the fact that about half (51 percent) say they have been uninsured for 2 years or more.
As the Centers for Medicare & Medicaid Services prepares to finalize a plan to pay physicians for discussing end-of-life treatment options with Medicare patients, this month’s Kaiser Health Tracking Poll finds that about 8 in 10 of the public favors Medicare and private insurance covering such discussions and about 9 in 10 say doctors should have these discussions with their patients. However, relatively few (17 percent) say they’ve had such discussions with a doctor or other health care provider, while half of the public says they would want to have such a discussion. Overall, opinion of the health care law has remained divided with similar shares reporting favorable views (41 percent) and unfavorable views (45 percent), with opinion starkly divided by party. The Kaiser Health Policy News Index also finds that the 2016 presidential election is the most widely followed news story included in this month’s Index, placing far ahead of health policy news stories.
Public Strongly Favors End-of-Life Conversations Between Doctors and Patients, With About Eight in 10 Saying Medicare and Other Insurers Should Cover These Visits
Six in 10 Oppose ‘Cadillac Plan Tax’ on High-Cost Health Plans Set to Take Effect in 2018, But Cost Savings Argument Can Change Some Opinions Views on the Affordable Care Act Remain Divided: 45% Unfavorable, 41% Favorable As the Centers for Medicare & Medicaid Services prepares to finalize a plan…
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman discusses why public concern over drug prices is the “tip of the iceberg” representing broader concerns about out-of-pocket health care costs. All previous columns by Drew Altman are available online.
In this column for The Wall Street Journal’s Think Tank, Drew Altman discusses why public concern over drug prices is the “tip of the iceberg” representing broader concerns about out-of-pocket health care costs.
With renewed discussion of the high cost of prescription drugs recently, the August Kaiser Health Tracking poll finds that most Americans feel that drug costs are unreasonable and that drug companies put profits before people. At the same time, the public largely values the role prescription drug companies play, with most saying that prescription drugs developed in the past two decades have made the lives of people in the U.S. better, including about 4 in 10 who say a lot better. When it comes to their views of the Affordable Care Act (ACA) this month, the American public remains divided in their opinion of the law. Those who favor repeal are divided on whether the law should be replaced with a Republican-sponsored alternative or if it should be repealed and not replaced